Enrolling by invitationNCT06472362

Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Royal Brompton & Harefield NHS Foundation Trust
Principal Investigator: Elisabetta A Renzoni
Royal Brompton and Harefield Hospitals
Intervention: HRCT biomarkers(diagnostic_test)
Enrollment: 1000 enrolled
Eligibility: 18-99 years · All sexes
Timeline: 2024 – 2026

Study locations (7)

Bichat-Claude Bernard hospital, Paris, France
Hanover Medical School, Hanover, Germany
Marche Polytechnic University, Ancona, Italy
Sassari University, Sassari, Italy
Siena University Hospital, Siena, Italy
Leeds Hospital/University of Leeds, Leeds, United Kingdom
Royal Brompton Hospital, London, United Kingdom

Collaborators

Imperial College London · Royal Free and University College Medical School · The Leeds Teaching Hospitals NHS Trust · Hannover Medical School · University of Siena · Università Politecnica delle Marche · Azienda Ospedaliero Universitaria di Sassari · Bichat Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06472362 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials